UK markets closed

Novo Nordisk A/S (0QIU.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
838.06+3.95 (+0.47%)
At close: 06:45PM BST

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • S
    SLk
    My dreams came through with the help of this great platform, I call it great because at first I was doubting the platform, not until I achieve a new car with the profit i got, so I followed the queue and got my book shop, You can contact him on Wh**atsApp✅ +1 (702) 381‑3007 OR Te~le~gram ✅@davispierce
  • D
    Dr_M_Vonnostrand
    i cant find anything bad in this ER. what did i miss?
  • h
    henry
    NVO was just 110 AH yp $3.25. now up .40 cents

    Look out Monday here comes $110 plus
  • C
    Carlos
    What is the dividend for the ADR in $US dollars ??
  • J
    Jeremy
    Since the share price drop seems to be a mystery to everyone, let me spell it out: Q4 sales were 38.3B DKK, Q1 Sales were 42B, Q2 sales were 41.3B (i.e. -0.7B vs Q2). Share price dropped because sales shrunk vs. Q1. NVO did raise full year guidance, but I think the market knew the guidance was conservative to begin with, and thus had much higher expectations.
  • F
    Fred
    I have been holding 400 shares since the 2018. This dip was too hard to resist. Bought another 100 shares at the close. The numbers look too good to pass up!
  • l
    li
    NVO is having trouble keeping up with demand for the diabetic community due to doctors prescribing for weight loss. Australia and Israel for example. And it's just the beginning for the weight loss market.
  • D
    DC
    once Wegovy in pill form make it Over the Counter at 50 bucks a month. Half the USA population would be on it. That would easily be more than a billion a month. At 50 a month only need 20 million people.
  • B
    Bryce
    Where are current comments concerning NVO & its sales growth for Ozempic & Wegovy?
  • L
    Larry
    What is the size of the impact on Novo Nordisk for US States, and recently California indicating that will manufacture their own low cost insulin to support medical programs. The article below indicates that across several states Eli and Sanofi have already moved to $35 per month for patients programs yet Novo is still up at $99. Is there a huge risk here, given that, I assume, insulin is still a very large percentage of Novo's income?
  • J
    John Smith
    Ozempic sales are going to go ballistic over the next few years. Shortages in the U.S, Israel and Australia. Stock a bit overpriced rn IMO, but will be a great long term hold.
  • E
    EINHORN
    Strong us dollar helps this company!!!
  • J
    John
    It appears that the stock is lower because of the slight reduction in Revs from Q1 to Q2. But historically this has been the case (in both 2021 and 2020, sales decreased from Q1 to Q2 then took off the rest of the year). And they are projecting increases (in fact adjusting up) the remainder of 2022 as well. My question is why sales (historically) drop in Q2 vs Q1? Is there a good reason?
  • L
    Larry
    Sold over half my holding a while back - great company but I think the market expectation has got well ahead of itself. This stock is still trading on a P/E of 35 almost double what it was a couple of years back when it had just about 12% less income.
    I suspect this will drift below $90 at some point, but on my remaining holding I think it's for the long term so won't abandon any more of my holding.
  • E
    EINHORN
    Many of our patient can't afford insulin Something has to be done. The party for the working class, is at least trying something!!
  • F
    Fred
    Looks like all the shorts are still asleep....
  • E
    ExpertReader
    Nvo is a great stock BUT California's decision to manufacture insulin represents a huge threat to all insulin manufacturers. The price fixing gouging for a life and death generic medication is immoral. I believe in the free market, but this isn’t a free market. Insulin is a market dominated by few multinational companies who have taken advantage in a wink wink on gouging customers through an imperfect distribution system. My opinion of course. Don’t take this a factual but as what I see in the press consistently
  • W
    Wing
    $237 BB CAP, am sure debts are a horror
  • D
    DC
    NVO reps will be outside of Walmarts handing out free samples of Wegovy. Lilly reps will be giving their samples with roll of TP